The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
Open accessPublished version of a preprint
Abstract
The serum level of RBD-binding antibodies correlates with SARS-CoV-2 neutralization and can be used for population-level surveillance.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The receptor binding domain (RBD) of SARS-CoV-2 spike protein had been identified to play a key role in helping coronaviruses to enter human cells.
“the receptor binding domain (RBD) of SARS-CoV-2 spike protein had been identified to play a key role in helping coronaviruses to enter human cells”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [8]
The RBD can induce strong humoral and cellular immune responses when used as an antigen in various SARS-CoV and MERS-CoV studies.
“the RBD can induce strong humoral and cellular immune responses when used as an antigen in various SARS-CoV and MERS-CoV studies),8, 9, 10”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [8]
The Results section on recombinant RBD antigens reports antibody binding in sera from animals immunized with SARS-CoV-1, but does not say they were immunized with RBD. The Study design describes using RBD to detect antibodies, not to induce immune responses. Searches for MERS-CoV and cellular immune responses found no passage addressing the claimed immunization findings. (LLM, conf=0.76)
Experimental — accuracy not yet measuredThe vast majority of SARS-CoV-2 infected individuals seroconvert within 5-15 days post-symptom onset, with about 90% seroconversion by day 10.
“The vast majority of SARS-CoV-2 infected individuals seroconvert within 5–15 days PSO, with ∼90% seroconversion by day 10 PSO (Long et al., 2020; Rydyznski Moderbacher et al., 2020; Premkumar et al., 2020; Ripperger et al., 2020; Suthar et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Premkumar et al., 2020
The receptor binding domain and N-terminal domain are immunodominant targets of neutralizing antibodies elicited by COVID-19 vaccines or SARS-CoV-2 infection.
“both being immunodominant targets of neutralizing antibodies elicited by COVID-19 vaccines or by SARS-CoV-2 infection (5, 6).”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,539 · see citing works
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045 · see citing works
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607 · see citing works
Li, Z., Yi, Y., Luo, X., Xiong, N., Liu, Y., Li, S., Sun, R., Wang, Y., Hu, B., Chen, W., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25727 · Cited by 1,772 · see citing works
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · see citing works
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,665 · see citing works
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614 · see citing works
Virology, Epidemiology, Pathogenesis, and Control of COVID-19
Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. (2020) · Viruses · doi:10.3390/v12040372 · Cited by 1,604 · see citing works
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Guo, L., Ren, L., Yang, S., Xiao, M., Chang, D., Yang, F., Cruz, C. S. D., Wang, Y., Wu, C., Xiao, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa310 · Cited by 1,585 · see citing works
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,253 · see citing works
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754 · see citing works
Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019Preprint
Zhao, J., Yuan, Q., Wang, H., et al. (2020) · medRxiv · doi:10.1101/2020.03.02.20030189 · Cited by 510 · see citing works
Serological assays for emerging coronaviruses: Challenges and pitfalls
Meyer, B., Drosten, C., & Müller, M. A. (2014) · Virus Research · doi:10.1016/j.virusres.2014.03.018 · Cited by 405 · see citing works
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
Lv, H., Wu, N. C., Tsang, O. T.-Y., Yuan, M., Perera, R. A. P. M., Leung, W.-S., So, R. T. Y., Chan, J. M. C., Yip, G. K., Chik, T. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107725 · Cited by 401 · see citing works
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus
Yount, B., Curtis, K. M., Fritz, E. A., Hensley, L. E., Jahrling, P., Prentice, E., Denison, M., Geisbert, T., & Baric, R. (2003) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1735582100 · Cited by 394 · see citing works
Self-citationSerological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
Perera, R. A. P. M., Mok, C. K. P., Tsang, O. T., Lv, H., Ko, R. L., Wu, N. C., Yuan, M., Leung, W.-S., Chan, J. M., Chik, T. S., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.16.2000421 · Cited by 322 · see citing works
Scobey, T., Yount, B. L., Sims, A. C., Donaldson, E. F., Agnihothram, S. S., Menachery, V. D., Graham, R. L., Swanstrom, J., Bove, P. F., Kim, J. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311542110 · Cited by 283 · see citing works
Self-citationLiu, W. Y., Fontanet, A. L., Zhang, P., Zhan, L., Xin, Z., Baril, L., Tang, F., Lv, H., & Cao, W. (2006) · The Journal of Infectious Diseases · doi:10.1086/500469 · Cited by 282 · see citing works
Hsueh, P., Huang, L., Chen, P., Kao, C., & Yang, P. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01009.x · Cited by 255 · see citing works
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227 · see citing works
The important role of serology for COVID-19 control
Winter, A. K., & Hegde, S. T. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30322-4 · Cited by 218 · see citing works
Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity
Döhla, M., Boesecke, C., Schulte, B., Diegmann, C., Sib, E., Richter, E., Eschbach-Bludau, M., Aldabbagh, S., Marx, B., Eis‐Hübinger, A. M., et al. (2020) · Public Health · doi:10.1016/j.puhe.2020.04.009 · Cited by 176 · see citing works
Che, X., Qiu, L., Liao, Z., Wang, Y., Wen, K., Pan, Y., Hao, W., Mei, Y., Cheng, V. C., & Yuen, K. (2005) · The Journal of Infectious Diseases · doi:10.1086/430355 · Cited by 165 · see citing works
Chan, K., Chan, J. F., Tse, H., Chen, H., Lau, C. C.-Y., Cai, J., Tsang, A. K. L., Xiao, X., To, K. K., Lau, S. K. P., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.03.015 · Cited by 157 · see citing works
Patrick, D. M., Petric, M., Skowronski, D. M., Guasparini, R., Booth, T. F., Krajden, M., McGeer, P. L., Bastien, N., Gustafson, L., Dubord, J., et al. (2006) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2006/152612 · Cited by 152 · see citing works
Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infectionsPreprint
Lv, H., Wu, N. C., Tsang, O. T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.15.993097 · Cited by 101 · see citing works
Maache, M., Komurian-Pradel, F., Rajoharison, A., Perret, M., Berland, J., Pouzol, S., Bagnaud, A., Duverger, B., Xu, J., Osuna, A., et al. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.13.3.409-414.2006 · Cited by 40 · see citing works
Agnihothram, S., Menachery, V. D., Yount, B. L., Lindesmith, L. C., Scobey, T., Whitmore, A. C., Schäfer, A., Heise, M. T., & Baric, R. S. (2018) · Journal of Virology · doi:10.1128/jvi.00027-18 · Cited by 36 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · see citing works
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860 · see citing works
Self-citationRydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790 · see citing works
“This RBD sequence is 346 amino acids in length, corresponding to amino acids 319-591 of the Spike protein sequences in the Protein Data Bank (PDB) deposited by Premkumar et al., 2020 (PDB 6VSB) and for the reference strain Wuhan-Hu-1 (PDB 6XR8).”
Self-citationSeow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120 · see citing works
Self-citationBarnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795 · see citing works
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients
Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822 · see citing works
Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
Kaneko, N., Kuo, H.-H., Boucau, J., Farmer, J. R., Allard-Chamard, H., Mahajan, V. S., Piechocka-Trocha, A., Lefteri, K., Osborn, M., Bals, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.025 · Cited by 734 · see citing works
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., et al. (2022) · Science · doi:10.1126/science.abn7591 · Cited by 367 · see citing works
Nguyen-Contant, P., Embong, A. K., Kanagaiah, P., Chaves, F. A., Yang, H., Branche, A. R., Topham, D. J., & Sangster, M. Y. (2020) · mBio · doi:10.1128/mbio.01991-20 · Cited by 204 · see citing works
de Alwis, R., Gan, E. S., Chen, S., Leong, Y. S., Tan, H. C., Zhang, S. L., Yau, C., Low, J. G. H., Kalimuddin, S., Matsuda, D., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.001 · Cited by 191 · see citing works
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Ku, Z., Xie, X., Davidson, E., Ye, X., Su, H., Menachery, V. D., Li, Y., Yuan, Z., Zhang, X., Muruato, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20789-7 · Cited by 160 · see citing works
Self-citationOved, K., Olmer, L., Shemer-Avni, Y., Wolf, T., Supino-Rosin, L., Prajgrod, G., Shenhar, Y., Payorsky, I., Cohen, Y., Kohn, Y., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100651 · Cited by 129 · see citing works
Antibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns
Baumgarth, N., Nikolich-Žugich, J., Lee, F. E.-H., & Bhattacharya, D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000839 · Cited by 84 · see citing works
Chen, G.-L., Li, X.-F., Dai, X.-H., Li, N., Cheng, M.-L., Huang, Z., Shen, J., Ge, Y.-H., Shen, Z.-W., Deng, Y.-Q., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00280-9 · Cited by 82 · see citing works
Steffen, T. L., Stone, E. T., Hassert, M., Geerling, E., Grimberg, B. T., Espino, A. M., Pantoja, P., Climent, C., Hoft, D. F., George, S. L., et al. (2020) · doi:10.1101/2020.08.21.261727 · Cited by 25 · see citing works
Zhou, C., Sun, M., Huang, X., Liu, P., Ouyang, Z., Wu, M., Yuan, L., Chen, J., Shu, W., Cao, T., et al. (2025) · hLife · doi:10.1016/j.hlife.2025.04.008 · Cited by 4 · see citing works
- Authors
- Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., Edwards, C. E., Weimer, E., Scherer, E. M., Rouphael, N., Edupuganti, S., Weiskopf, D., Tse, L. V., Hou, Y. J., Margolis, D., Sette, A., Collins, M. H., Schmitz, J., Baric, R. S., & de Silva, A. M.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Emory University (US)
- La Jolla Institute for Immunology (US)
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
- Corresponding author
- Premkumar, Lakshmanane
- ORCID
- Premkumar, Lakshmanane
- Segovia-Chumbez, Bruno
- Jadi, Ramesh
- Martinez, David R.
- Raut, Rajendra
- Markmann, Alena J.
- Cornaby, Caleb
- Bartelt, Luther
- Weiss, Susan
- Edwards, Caitlin E.
- Weimer, Eric
- Scherer, Erin M.
- Rouphael, Nadine
- Edupuganti, Srilatha
- Weiskopf, Daniela
- Tse, Longping V.
- Hou, Yixuan J.
- Margolis, David
- Sette, Alessandro
- Collins, Matthew H.
- Schmitz, John
- Baric, Ralph S.
- de Silva, Aravinda M.
- Venue
- Science Immunology
- Published
- 2020-06-26
- Volume
- 5
- Issue
- 48
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7292505
- OpenAlex
- W3034680516
- Cited by
- 868
- References
- 28
- Citations by year
- 2026: 29 · 2025: 44 · 2024: 75 · 2023: 122 · 2022: 204 · 2021: 273 · 2020: 121
- FWCI
- 23.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science Immunology (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institute of Allergy and Infectious Diseases (75N9301900065, T32 AI007151)
- Burroughs Wellcome Fund
- University of North Carolina at Chapel Hill
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, receptor binding domain, spike protein, antibody response, serological diagnosis, neutralizing antibodies, antibody kinetics, hyperimmune sera, zoonotic coronaviruses, sensitivity and specificity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
